Core Viewpoint - The January non-farm payrolls report revealed 130,000 new jobs and a drop in unemployment to 4.3%, leading to a reduction in expected Federal Reserve rate cuts for the year, making ultra-high-yield dividend stocks more attractive for income-focused investors [1][2]. Group 1: Economic Indicators - The non-farm payrolls report for January showed a surprising addition of 130,000 jobs, significantly exceeding Wall Street's expectations of 70,000-80,000 [1]. - Unemployment decreased to 4.3%, indicating a robust job market [1]. Group 2: Federal Reserve Rate Cuts - Predictions for 2.5 rate cuts this year were reduced to 2 following the jobs report, with potential for no cuts until summer if the upcoming consumer price index is below expectations [1]. - The expectation of prolonged higher interest rates diminishes the likelihood of rate cuts, making high-yield dividend stocks more appealing [1]. Group 3: Investment Opportunities - Ultra-high-yield stocks, offering dividends between 7% and 10%, are highlighted as attractive options for investors seeking passive income in a high-rate environment [1]. - Ares Capital Corporation, yielding 9.94%, specializes in financing solutions for middle-market companies and has received a Buy rating from 12 analysts [1][2]. - Energy Transfer, with a 7.16% distribution yield, operates a vast network of energy assets across the U.S. and has an Overweight rating from JPMorgan with a $21 target price [2]. - Healthpeak Properties, a REIT focused on healthcare real estate, offers a 7.24% dividend and has an Outperform rating with a $20 target price [2]. - Plains All American Pipeline, yielding 7.68%, operates midstream energy infrastructure and is poised for a breakout, with a Buy rating and a $25 target price from UBS [2]. - Starwood Property Trust, with a 10.60% dividend yield, operates in various segments including commercial and residential lending, and has an Outperform rating with a $21 target [2].

We screened our ultra-high-yield dividend stocks database for quality companies yielding between 7% and 10%. Five of our favorite companies fall into this group, and all are rated Buy by the top Wall Street firms we cover.Less competition from future rate cuts - When people expect rate cuts, they often buy growth stocks (tech, etc.), anticipating they'll soar when rates drop. But if cuts aren't coming, investors shift focus back to "get paid while you wait" strategies, making dividend income more valuable r ...

Core Viewpoint - Goldman Sachs initiated coverage of Healthpeak Properties Inc. with a Neutral rating and a price target of $17, highlighting improving occupancy and cash flow visibility in senior housing investments [1] Group 1: Company Overview - Healthpeak Properties Inc. operates as a fully integrated healthcare REIT, focusing on acquiring, developing, owning, leasing, and managing healthcare real estate across the United States [4] Group 2: Recent Developments - Healthpeak's portfolio has significantly changed since 2019, particularly due to the merger with Physicians Realty Trust, which closed on March 1, 2024, effectively doubling the size of its outpatient medical portfolio [2] - On January 7, Healthpeak announced plans to form and take public Janus Living, Inc., a new REIT focused entirely on senior housing, contributing its 34-community, 10,422-unit senior housing portfolio to Janus Living [3]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported FFO as adjusted of $0.47 per share and AFFO of $0.40 per share, with total same-store cash NOI growth of 3.9% [15][16] - For the full year 2025, FFO as adjusted was $1.84 per share and AFFO was $1.69 per share, with total same-store cash NOI growth of 4% [16] - The company ended the year with a net debt to adjusted EBITDA ratio of 5.2x and $2.4 billion in liquidity [18] Business Line Data and Key Metrics Changes - Outpatient medical segment represented over 50% of portfolio income, achieving same-store growth of 3.9% and 91% total occupancy [4][16] - The lab segment ended the year with 1.5% same-store growth and total occupancy of 77%, impacted by the recent Gateway acquisition [17] - Senior housing segment reported 12.6% same-store growth, with 16.7% growth in Q4, driven by favorable supply and demand fundamentals [18] Market Data and Key Metrics Changes - The Bay Area led all life science markets in Q4 2025 in absorption and leasing activity, with significant tenant demand [8] - The outpatient sector is benefiting from a shift in care delivery to lower-cost outpatient settings, supported by policy changes from CMS [5] Company Strategy and Development Direction - The company is focused on strengthening its portfolio through strategic acquisitions, including the Gateway acquisition and the formation of a pure-play senior housing REIT, Janus Living [10][21] - The merger with Physicians Realty Trust has created a strong platform in the outpatient sector, allowing for profitable internalization of property management [4][5] - The company plans to recycle capital through $1 billion or more in asset sales and recapitalizations in 2026 [21] Management's Comments on Operating Environment and Future Outlook - Management noted an improvement in capital raising and M&A activity, indicating early signs of a recovery in the life science sector [6][20] - The company expects FFOs adjusted to range from $1.70 to $1.74 per share for 2026, with same-store NOI growth forecasted between -1% to +1% [19] - Management emphasized the importance of maintaining a strong balance sheet and disciplined capital allocation to pursue strategic investments [19] Other Important Information - The company has $360 million of additional relationship-driven acquisitions in its senior housing pipeline, expected to close in Q1 2026 [13] - The company filed a confidential S-11 with the SEC for the Janus Living IPO, with expectations to close the offering in the first half of 2026 [14] Q&A Session Summary Question: Can you discuss the Gateway acquisition and its complement to the existing portfolio? - Management expressed excitement about the Gateway acquisition, viewing it as an opportunity rather than a concern about vacancy, and highlighted the strategic fit within their existing footprint [25][26] Question: What is the expected cadence of lab occupancy throughout the year? - Management indicated that total occupancy should improve by year-end 2026, contingent on continued positive trends in capital markets [30] Question: Can you provide more details on the lab leasing activity? - Management noted that the pipeline is strong, with a shift towards new leasing, and emphasized the importance of the current market conditions [36] Question: How will the lab occupancy losses impact 2026 FFO? - Management clarified that the impact is a combination of various factors, including occupancy losses and higher refinancing costs, with expectations for gradual recovery [41][42] Question: What is the strategy regarding refinancing activity? - Management stated that they will be opportunistic in accessing the market for refinancing, focusing on maturities ahead of them [58]

Healthpeak Properties (NYSE:DOC) Q4 2025 Earnings call February 03, 2026 10:00 AM ET Company ParticipantsAndrew Johns - SVP of Investor RelationsAustin Wurschmidt - DirectorFarrell Granath - Equity Research AssociateJames Kammert - Managing DirectorJamie Feldman - Managing DirectorJohn Pawlowski - Managing DirectorJuan Sanabria - Managing DirectorKelvin Moses - CFONick Joseph - Managing DirectorNick Yulico - Managing DirectorOmotayo Okusanya - Managing DirectorRich Anderson - Managing DirectorScott Bohn - C ...

Financial Data and Key Metrics Changes - For Q4 2025, the company reported FFO as adjusted of $0.47 per share and AFFO of $0.40 per share, with total same-store cash NOI growth of 3.9% [15] - For the full year 2025, FFO as adjusted was $1.84 per share and AFFO was $1.69 per share, with total same-store cash NOI growth of 4% [16] - The company ended the year with a net debt to adjusted EBITDA ratio of 5.2x and $2.4 billion in liquidity [19] Business Line Data and Key Metrics Changes - Outpatient medical segment represented over 50% of portfolio income, achieving 3.9% same-store growth and 91% total occupancy [3][16] - The lab segment ended the year with 1.5% same-store growth and total occupancy of 77%, impacted by the recent Gateway acquisition [17] - Senior housing segment reported 12.6% same-store growth, with 16.7% growth in Q4, driven by favorable supply and demand fundamentals [18] Market Data and Key Metrics Changes - The outpatient sector is benefiting from a shift in care delivery to lower-cost outpatient settings, supported by policy changes from CMS [4] - The Bay Area led all life science markets in Q4 2025 in absorption and leasing activity, with significant tenant demand [8] Company Strategy and Development Direction - The company is focused on strengthening its portfolio through strategic acquisitions, including the Gateway acquisition and the formation of a pure-play senior housing REIT, Janus Living [10][11] - The company plans to recycle capital through $1 billion or more in asset sales and recapitalizations in 2026 [21] - The company aims to leverage its strong market position and relationships to capture demand as the life science sector recovers [6] Management's Comments on Operating Environment and Future Outlook - Management noted an improvement in capital raising and M&A activity, indicating early signs of a recovery in the life science sector [5] - The company expects FFOs adjusted to range from $1.70 to $1.74 per share for 2026, with total same-store NOI growth forecasted between -1% to +1% [19] - Management highlighted the importance of maintaining a strong balance sheet and disciplined capital allocation to pursue strategic investments [19] Other Important Information - The company has $360 million of additional relationship-driven acquisitions in its senior housing pipeline, expected to close in Q1 2026 [12] - The company filed a confidential S-11 with the SEC for the Janus Living IPO, with expectations to close the offering in the first half of 2026 [13] Q&A Session Summary Question: Can you discuss the Gateway acquisition and its complement to the existing portfolio? - Management expressed excitement about the Gateway acquisition, viewing it as an opportunity rather than just taking on vacancy, and highlighted the strategic fit within their existing footprint [25][26] Question: What is the outlook for lab segment occupancy throughout the year? - Management indicated that total occupancy should improve by year-end 2026, contingent on continued positive trends in capital markets [28][30] Question: Can you provide details on the lab leasing activity under execution or LOI? - Management noted that the current pipeline is significantly improved compared to the previous year, with a shift towards new leasing [34][35] Question: What is the impact of lab occupancy losses on 2026 FFO? - Management clarified that the $0.12 impact on earnings is due to various factors, including occupancy losses and higher refinancing costs [41][42] Question: How is the company addressing the 2026 expirations for life science? - Management stated that a substantial majority of expirations are in South San Francisco, where they have strong tenant relationships, and they are optimistic about capturing renewals [61][62]

I wrote an article when Healthpeak ( DOC ) was trading at $18 a share, rating it a Buy. Well, that call hasn’t turned out to be as profitable as I would have liked. I continued to accumulate shares as it dipped and haveWith a master’s in economics and 15 years of experience spanning both public and private sectors, I bring a global perspective to my investing insights. Having lived and worked in Colombia, Costa Rica, Chile, and Myanmar, I have a firsthand understanding of diverse economic systems, which I i ...

Core Insights - Healthpeak Properties, Inc. reported fourth-quarter 2025 funds from operations (FFO) as adjusted per share of 47 cents, exceeding the Zacks Consensus Estimate of 45 cents and slightly up from 46 cents in the prior-year quarter [1][8] - The company generated revenues of $719.4 million, surpassing the Zacks Consensus Estimate of $699.5 million, reflecting a year-over-year increase of 3.1% [2] - Full-year FFO, as adjusted, was $1.84 per share, above the Zacks Consensus Estimate of $1.83, and improved 1.7% year over year [2] Financial Performance - Healthpeak reported a 3.9% year-over-year growth in total merger-combined same-store cash (adjusted) net operating income (NOI) [4] - The outpatient medical and continuing care retirement community (CCRC) segments experienced year-over-year growth of 4.1% and 16.7%, respectively, while the lab segment saw a decline of 0.3% [4] - Interest expenses increased by 14.4% year over year to $80.6 million [5] Strategic Initiatives - The company announced the formation of Janus Living, Inc., a senior housing REIT, and plans for an initial public offering (IPO) [3] - Healthpeak is restructuring its portfolio by selling stabilized assets and reinvesting the proceeds into value-accretive investments [3] - The company is focusing on technology innovation initiatives to enhance automation, decision-making speed, and client service [3] Balance Sheet - Healthpeak ended the fourth quarter with cash and cash equivalents of $467.5 million, a significant increase from $91 million as of September 30, 2025 [6] - The net debt to adjusted EBITDAre ratio was 5.2X as of December 31, 2025 [6] 2026 Outlook - The company expects FFO as adjusted per share to be between $1.70 and $1.74, while the Zacks Consensus Estimate is currently at $1.84 [7] - Total merger-combined same-store cash (adjusted) NOI growth is projected to range from negative 1% to 1% [7]

Healthpeak Properties, Inc. (DOC) is a fully integrated real estate investment trust (REIT) based in Denver, Colorado. Valued at a market cap of $12 billion, the company owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery. This healthcare REIT has considerably underperformed the broader market over the past 52 weeks. Shares of DOC have declined 18.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 15.5%. However, on a YTD basis, the st ...

Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to FFO of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of +3.37%. A quarter ago, it was expected that this health care real estate investment trust would post FFO of $0.45 per share when it actually produced FFO of $0.46, delivering a surprise of +2.22%.Over the last f ...